Montek (Pertechnetate (99mtc) Sodium)

Montek is used in nuclear medicine to image organs that concentrate sodium‑iodide symporter substrates.

• Thyroid imaging: provides functional visualization of thyroid tissue to assess uptake and detect nodules or dysfunction.
• Salivary gland imaging: delineates salivary gland structure and function, aiding diagnosis of obstruction or inflammation.
• Renal imaging: evaluates renal perfusion and function by tracing tracer uptake and excretion.
• Gastric mucosa imaging: highlights gastric mucosal activity to detect ulcers or Helicobacter pylori‑related changes.
• Whole‑body scintigraphy: enables detection of ectopic uptake sites for comprehensive diagnostic assessment.

• Technetium‑99m pertechnetate sodium emits gamma photons that are detected by scintillation cameras. After intravenous or ocular administration, the anion is actively transported into cells expressing the sodium‑iodide symporter, concentrating in thyroid follicular cells, salivary glands, gastric mucosa and other tissues. The short half‑life of Tc‑99m (≈6 hours) provides high‑resolution images with minimal radiation exposure. Image acquisition occurs within minutes, allowing dynamic assessment of tracer distribution and organ function.

Adverse reactions to Montek are generally infrequent but may occur following administration of the radiotracer.

Common Side Effects

• Nausea: mild transient feeling of stomach upset.
• Vomiting: occasional brief episodes after injection.
• Headache: mild to moderate discomfort.
• Dizziness: transient light‑headedness.
• Injection site pain: brief discomfort at the venipuncture site.
• Flushing: temporary reddening of skin.

Serious or Rare Side Effects

• Allergic reaction: urticaria, itching or rash.
• Anaphylaxis: severe, potentially life‑threatening hypersensitivity.
• Severe hypotension: marked drop in blood pressure requiring monitoring.
• Radiation‑induced tissue injury: rare localized damage at high activity levels.
• Thyroid storm: extremely rare exacerbation of hyperthyroidism.

When using Montek, several precautions should be observed to ensure patient safety and optimal imaging results.

• Pregnancy: assess risk‑benefit ratio, as fetal radiation exposure is possible.
• Breastfeeding: consider temporary cessation or interruption to avoid infant exposure.
• Renal impairment: evaluate renal function; altered clearance may affect image quality.
• Iodine‑containing contrast agents: avoid administration within 24 hours to prevent uptake interference.
• Thyroid disorders: abnormal thyroid function may modify tracer distribution and interpretation.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Montek may interact with certain substances that influence tracer uptake or patient response.

Major Interactions (Avoid)

• Iodine‑containing drugs: can competitively inhibit pertechnetate uptake, reducing image quality.
• Amiodarone therapy: high iodine content may block tracer accumulation.
• Recent radioactive iodine (I‑131) therapy: residual activity interferes with diagnostic imaging.
• Thyroid hormone replacement: may alter thyroid uptake patterns.
• High‑dose corticosteroids: can affect inflammatory imaging results.

Moderate Interactions (Monitor Closely)

• Diuretics: may modify renal excretion of the tracer.
• Antihistamines: could mask early signs of allergic reactions.
• Beta‑blockers: may influence heart rate during cardiac‑related imaging.
• Calcium supplements: large doses might affect gastric mucosa uptake.
• Sedatives: may contribute to dizziness or hypotension.